Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

被引：5
|
作者：
Hussain, Syed A.
Maroto, Pablo
Climent, Miguel Angel
Bianchini, Diletta
Jones, Robert Hugh
Lin, Chia-Chi
Wang, Shian-Shiang
Dean, Emma
Crossley, Kate
Schlieker, Laura
Bogenrieder, Thomas
De Bono, Johann S.
机构：
[1] Univ Sheffield, Acad Unit Oncol, Dept Oncol & Metab, Sheffield, S Yorkshire, England
[2] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Inst Canc Res, London, England
[5] Royal Marsden, London, England
[6] Velindre Canc Ctr, Cardiff, S Glam, Wales
[7] Cardiff Univ, Cardiff, S Glam, Wales
[8] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[9] Taichung Vet Gen Hosp, Taichung, Taiwan
[10] Christie NHS Fdn Trust, Manchester, Lancs, England
[11] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[12] Boehringer Ingelheim Pharma Gmbh & Co KG, Staburo Gmbh & Co KG, Munich, Germany
[13] Boehringer Ingelheim RCV, Vienna, Austria
[14] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Dept Urol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5030
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Randomized phase II study of docetaxel (D) plus abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial
    Climent Duran, Miguel Angel
    Font, Albert
    Duran, Ignacio
    Puente, Javier
    Castellano, Daniel
    Isabel Saez, M.
    Mendez Vidal, Maria Jose Jose
    Santander, Carmen
    Arranz Arija, Jose Angel
    Gonzalez del Alba, Aranzazu
    Sanchez-Hernandez, Alfredo
    Esteban, Emilio
    Alonso Gordoa, Teresa
    Maroto, Pablo
    Lazaro Quintela, Martin Emilio
    Cassinello, Javier
    Perez Valderrama, Begona
    Juan Fita, Maria Jose
    Mellado, Begona
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] High exosomal PD-L1 expression in relation to lymph node progression in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (abi) or enzalutamide (enza).
    Conteduca, Vincenza
    Del Re, Marzia
    Scarpi, Emanuela
    Crucitta, Stefania
    Gurioli, Giorgia
    Restante, Giuliana
    Cucchiara, Federico
    Lolli, Cristian
    Brighi, Nicole
    Schepisi, Giuseppe
    Casadei, Chiara
    Ulivi, Paola
    Beltran, Himisha
    Danesi, Romano
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17038 - E17038
  • [33] Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium
    Harzstark, A. L.
    Beer, T. M.
    Weinberg, V. K.
    Higano, C. S.
    Nordquist, L. T.
    Rosenberg, J. E.
    Alumkal, J. J.
    Yu, E. Y.
    Mi, J.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [34] Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Nauseef, Jones T.
    Christos, Paul J.
    Thomas, Charlene
    Nordquist, Luke T.
    Sternberg, Cora N.
    Beltran, Himisha
    Guervil, Sabrina
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    Molina, Ana M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [35] A randomized phase II trial of abiraterone, olaparib or abiraterone plus olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects.
    Reichert, Zachery
    Carneiro, Benedito A.
    Daignault-Newton, Stephanie
    Sullivan, Amanda
    Feng, Felix Yi-Chung
    Morgan, Todd Matthew
    Tomlins, Scott A.
    Chinnaiyan, Arul M.
    Hussain, Maha
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)
    Caffo, O.
    Palesandro, E.
    Nole, F.
    Gasparro, D.
    Mucciarini, C.
    Aieta, M.
    Zagonel, V.
    Iacovelli, R.
    De Giorgi, U. F. F.
    Rossetti, S.
    Fratino, L.
    Ermacora, P.
    Nicodemo, M.
    Giordano, M.
    Sartori, D.
    Scapoli, D.
    Verri, E.
    Maines, F.
    Pappagallo, G.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 333 - 333
  • [37] An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel.
    Harshman, Lauren Christine
    Gray, Kathryn P.
    Polacek, Laura
    Taplin, Mary-Ellen
    Choudhury, Atish Dipankar
    Pomerantz, Mark M.
    Bellmunt, Joaquim
    Yu, Channing
    Sun, Zijie
    Srinivas, Sandy
    Kantoff, Philip W.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Treatment efficacy of abiraterone (abi), enzalutamide (enza) or cabazitaxel (caba) in metastasic castration-resistant prostate cancer patients (mCRPC) after progression to docetaxel plus androgen deprivation therapy (ADT) in hormone sensible disease.
    Climent Duran, Miguel Angel
    Saez, M. Isabel
    Piulats, Josep M.
    Montesa, A.
    Chirivella, Isabel
    Gonzalez Forastero, Alejandro
    Caballero Diaz, Cristina
    Heras, Lucia
    Mellado, Begona
    Vazquez-Estevez, Sergio
    Olmos, David
    Duran, Ignacio
    Juan Fita, Maria Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [39] Abiraterone acetate plus prednisone (AAP) in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC) and prior diethylstilbestrol (DES) therapy: Preliminary results.
    Bastos, Diogo Assed
    Machado, Marcos Tobias
    Panhoca, Renato
    Pioner, Giovani Thomaz
    Werutsky, Gustavo
    Grings, Mariana
    Lopes, Lizis
    Gonzalez, Francisco
    Santos, Telma Murias
    Gidekel, Rosemarie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [40] Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.
    Small, E. J.
    Beer, T. M.
    Weinberg, V. K.
    Higano, C. S.
    Nordquist, L. T.
    Rosenberg, J. E.
    Alumkal, J. J.
    Yu, E. Y.
    Sun, J.
    Lin, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345